Steering Committee

Andrew Penn

MS, PMHNP-BC
Clinical Professor / Director of Clinical Nursing Operations
University of California, San Francisco, School of Nursing / Salma Health

Andrew Penn, MS, PMHNP is a Professor in the University of California, San Francisco, School of Nursing where his teaching has received the UCSF Academic Senate Distinction in Teaching Award, among other recognitions. Trained as a psychiatric/mental health nurse practitioner, he directs clinical nursing operations for Salma Health an early stage psychiatric interventional treatment clinical company. As a researcher, he has collaborated on psychedelics studies of psilocybin and MDMA in the Translational Psychedelics Research (TrPR) and the Carhart-Harris labs at UCSF. A leading voice in nursing, he is a cofounder of the Organization of Psychedelic and Entheogenic Nurses (OPENurses.org), advocating for the perspective of nurses in psychedelic therapy, he has published on psychedelics in the American Journal of Nursing, Frontiers in Psychiatry, The Journal of Humanistic Psychotherapy, and JAMA. An internationally invited speaker, he has lectured at SXSW, Aspen Health Ideas Festival, TEDx, the Singapore Ministry of Health, and Oxford University and can be found at Andrewpennnp.com.

2026 Sessions

Psychedelic Therapy After the Executive Order: Now What?

As psychedelic therapies gain visibility, clinicians are increasingly asked to interpret clinical research, evolving policy, and growing patient interest. This session provides a balanced, current view of the field, including a patient story that illustrates the lived experience of treatment. A targeted policy update focusing on what is known today and how existing frameworks may influence clinical practice in the immediate term. As well as a multidisciplinary panel of experts who will discuss the current state of psychedelics, offering practical insight to help clinicians navigate this evolving area of mental health care. 

Speaker

Tuesday, September 15 1:45–3:15 PM
Room Great Hall A
Faculty

Amber Capone

Co-Founder and CEO
VETS, Inc.

Amber Capone is a nationally recognized
leader, advocate, and changemaker in
veteran mental health and family resilience.
As Co-Founder and CEO of VETS, she
has built a globally respected nonprofit at the
forefront of expanding access to
psychedelic-assisted therapies for veterans
suffering from post-traumatic stress and
traumatic brain injury.
Since co-founding VETS in 2019, Amber has
helped grow the organization into a highimpact force for change—raising millions in
funding, supporting more than 1,300 veterans, and advancing
critical research and policy initiatives across
the country. Under her leadership, VETS has
become a trusted voice in the national
conversation around mental health
innovation and veteran care.
Amber has played a pivotal role in advancing
legislative efforts, including the
Texas Ibogaine Initiative (TII). Her ability to unite
lawmakers, researchers, and veteran
advocates has helped drive meaningful
progress toward safe, regulated access to
emerging therapies.

In addition to her advocacy work, Amber continues to
expand VETS’ cultural and educational impact through
storytelling. She was instrumental in the production and
release of In Waves and War, a powerful documentary
project that premiered on Netflix and brings visibility to the
veteran healing journey and the potential of psychedelicassisted therapies.
A two-time honoree on Inc.’s Female Founders 500 (2025
and 2026), Amber is widely recognized for her visionary
leadership, strategic insight, and unwavering commitment
to those who have served. Her work is grounded in a
deeply personal mission—to ensure that veterans and their
families have access to the most advanced care available.

Faculty

Marcus Capone

Founder
VETS: Veterans Exploring Treatment Solutions

Marcus Capone is a visionary entrepreneur, health innovator, and decorated Navy SEAL on a mission to rewrite the future of mental health. A veteran of U.S. Special Operations, Marcus retired from active duty in 2013 after a distinguished career that included multiple combat tours to Afghanistan and Iraq, earning numerous combat awards with valor at SEAL Team Ten and the legendary SEAL Team Six, the world's premier counter-terrorism unit.

As Chairman and Co-Founder of VETS: Veterans Exploring Treatment Solutions, Marcus leads a national movement that's shattered stigma and paved new trails in evidence-based, alternative therapies for U.S. veterans. By championing groundbreaking solutions and policy reform, Marcus and his team have delivered over $145 million in funding, research, and hope, unlocking public and private funding for innovative brain health treatments, empowering thousands of veterans and families to access truly transformative care.

Building on this legacy, Marcus founded TARA Mind, where he serves as CEO, to bring advanced, science-backed mental health treatments to those who need them most. TARA Mind's elite nationwide network of integrative clinics, providers, and therapists is revolutionizing modern behavioral healthcare, working alongside visionary employers and healthcare systems to redefine wellness benefits and ensure breakthrough therapies are accessible across America. Marcus and his team have built a proprietary AI platform to raise the standard of care, focused on data-driven outcomes. His story and leadership continue to move the needle, driving new standards in mental healthcare and wellbeing for diverse communities both in the US and across the globe.

Co-Chair

Rakesh Jain

MD, MPH
Clinical Professor
Texas Tech - Permian Basin

Rakesh Jain, MD, MPH, attended medical school at the University of Calcutta in India. He then attended graduate school at the University of Texas School of Public Health in Houston, where he was awarded a “National Institute/Center for Disease Control Competitive Traineeship”. His research thesis focused on impact of substance abuse. He graduated from the School of Public Health in 1987 with a Masters of Public Health (MPH) degree.

Dr. Jain served a three-year residency in Psychiatry at the Department of Psychiatry and Behavioral Sciences at the University of Texas Medical School at Houston. He followed that by obtaining further specialty training, by undergoing a two-year fellowship in Child and Adolescent Psychiatry. In addition, Dr. Jain completed a postdoctoral fellowship in Research Psychiatry at the University of Texas Mental Sciences Institute, in Houston. He was awarded the “National Research Service Award” for the support of this postdoctoral fellowship.

Steering Committee

Saundra Jain

MA, PsyD, LPC
Adjunct Clinical Affiliate, University of Texas at Austin School of Nursing;
Private Practice, Austin, Texas

Saundra Jain, MA, PsyD, LPC, is an Adjunct Clinical Affiliate in the School of Nursing at The University of Texas at Austin and a psychotherapist in private practice. Dr. Jain is a co-creator of WILD 5 – A Proven Path to Wellness and co-author of The Science and Practice of Wellness: Interventions for Happiness, Enthusiasm, Resilience, and Optimism (HERO). She is the co-creator of the Psychedelics and Wellness Survey (PAWS), exploring the intersection between psychedelics and wellness. She is the co-host of the newly launched podcast Happy Human 3.0, which explores how modern humans can move beyond merely surviving 21st-century stressors and begin to flourish by integrating neuroscience, positive psychiatry, and compassionate, human-centered care.

In addition, Dr. Jain serves on the Psych Congress Steering Committee, helping guide educational priorities and identify emerging needs in mental health practice. She also teaches with Fluence Training, a leading provider of psychedelic education for mental health professionals, where she serves as faculty in their certification programs in Psychedelic Harm Reduction and Integration (PHRI) and Ketamine-Assisted Psychotherapy (KAP).

Steering Committee

Andrew Penn

MS, PMHNP-BC
Clinical Professor / Director of Clinical Nursing Operations
University of California, San Francisco, School of Nursing / Salma Health

Andrew Penn, MS, PMHNP is a Professor in the University of California, San Francisco, School of Nursing where his teaching has received the UCSF Academic Senate Distinction in Teaching Award, among other recognitions. Trained as a psychiatric/mental health nurse practitioner, he directs clinical nursing operations for Salma Health an early stage psychiatric interventional treatment clinical company. As a researcher, he has collaborated on psychedelics studies of psilocybin and MDMA in the Translational Psychedelics Research (TrPR) and the Carhart-Harris labs at UCSF. A leading voice in nursing, he is a cofounder of the Organization of Psychedelic and Entheogenic Nurses (OPENurses.org), advocating for the perspective of nurses in psychedelic therapy, he has published on psychedelics in the American Journal of Nursing, Frontiers in Psychiatry, The Journal of Humanistic Psychotherapy, and JAMA. An internationally invited speaker, he has lectured at SXSW, Aspen Health Ideas Festival, TEDx, the Singapore Ministry of Health, and Oxford University and can be found at Andrewpennnp.com.

Steering Committee

Charles Raison

MD
Professor
University of Wisconsin-Madison

Charles Raison, MD, is a Professor of Human Ecology and Psychiatry in the Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin-Madison. Dr. Raison also serves as Director of Clinical and Translational Research for Usona Institute, as Director of the Vail Health Behavioral Health Innovation Center, Director of Research on Spiritual Health for Emory Healthcare and as Visiting Professor in the Center for the Study of Human Health at Emory University in Atlanta, GA. Dr. Raison’s research focuses on the examination novel mechanisms involved in the development and treatment of major depression and other stress-related emotional and physical conditions, as well as for his work examining the physical and behavioral effects of compassion training. More recently, Dr. Raison has taken a leadership role in the development of psychedelic medicines as potential treatments for major depression. He was named one of the world’s most influential researchers by Web of Science for the decade of 2010-2019 and has been honored with a Distinguished Alumni Award from Washington University School of Medicine. Dr. Raison received the Raymond Pearl Memorial Award from the Human Biology Association “in recognition of his contributions to our understanding of evolutionary biocultural origins of mental health and illness.” Dr. Raison has also won the 2024 Emory University Science on Spiritual Health Torch and Trumpet Award “for a career devoted to the mental and spiritual health of humanity by responding and attending to suffering with a compassionate heart and a keen scientific mind.”

Faculty

Matthew Zorn

JD

Cannabis Use and Mental Illness: What We Now Know (and Don’t)

Cannabis-related psychiatric complications are increasing due to rising THC potency, novel formulations, and widespread use among adolescents and young adults. This session reviews data on cannabis-induced psychosis, effects on depression and bipolar disorder, dose-response relationships, withdrawal, and risk reduction. Faculty will discuss assessment tools, cannabis tapering strategies, and treatment pathways for cannabis use disorder. Participants will gain practical guidance for counseling patients, addressing misconceptions, and integrating evidence-based interventions into clinical care.

Speaker

Tuesday, September 15 6:30–7:30 PM
Room Great Hall D
Substance Use Disorders
Steering Committee

Ilan Melnick

MD
Chief Medical Officer, Passageway Residences of Dade County,
Passageway Residences of Dade County

Ilan Melnick, MD, is the primary psychiatrist in two outpatient clinics in the Miami, Florida area, as well as a staff psychiatrist and Chief Medical Officer at Passageway Residences of Miami-Dade County. In addition, Dr. Melnick is a staff psychiatrist and Medical Director for Jewish Community Services and performs independent medical and psychiatric evaluations for Miami-Dade County police, fire, transit and aviation departments.

Dr. Melnick received his medical degree in Bayamon, Puerto Rico and went on to do his residency in psychiatry and fellowship in geriatric psychiatry at the University of Miami/Jackson Memorial Hospital.He continues to be involved in education as an Assistant Professor at Florida International University School of medicine. He continues to be involved in education through his role giving grand rounds at major universities and hospitals around the world.

Steering Committee

Andrew Penn

MS, PMHNP-BC
Clinical Professor / Director of Clinical Nursing Operations
University of California, San Francisco, School of Nursing / Salma Health

Andrew Penn, MS, PMHNP is a Professor in the University of California, San Francisco, School of Nursing where his teaching has received the UCSF Academic Senate Distinction in Teaching Award, among other recognitions. Trained as a psychiatric/mental health nurse practitioner, he directs clinical nursing operations for Salma Health an early stage psychiatric interventional treatment clinical company. As a researcher, he has collaborated on psychedelics studies of psilocybin and MDMA in the Translational Psychedelics Research (TrPR) and the Carhart-Harris labs at UCSF. A leading voice in nursing, he is a cofounder of the Organization of Psychedelic and Entheogenic Nurses (OPENurses.org), advocating for the perspective of nurses in psychedelic therapy, he has published on psychedelics in the American Journal of Nursing, Frontiers in Psychiatry, The Journal of Humanistic Psychotherapy, and JAMA. An internationally invited speaker, he has lectured at SXSW, Aspen Health Ideas Festival, TEDx, the Singapore Ministry of Health, and Oxford University and can be found at Andrewpennnp.com.

Not All Delusions are Schizophrenia: Understanding Delusional Disorders and the Overlap with Substance Induced Psychosis

While psychosis is common in schizophrenia or bipolar mania, there are many other causes of the psychosis symptoms. This session will help you learn to differentiate other causes of psychosis, including substance induced, delusional disorders, and medical causes of psychosis symptoms. Faculty will provide practical guidance on how to examine the temporal nature of the psychotic symptoms, the distinguishing features of different symptoms, and associated assessment technology, such as labs and imaging to arrive at a differential diagnosis. Utilizing a historic case presentation, learners will remember that it is sometimes not only the symptoms that are present, but also those that are absent, that help us to make a correct diagnosis. Participants will also gain practical skills for the management of these conditions.

Speaker

Wednesday, September 16 1:30–2:30 PM
Room 211-213
Psychotic Disorders
Steering Committee

Andrew Penn

MS, PMHNP-BC
Clinical Professor / Director of Clinical Nursing Operations
University of California, San Francisco, School of Nursing / Salma Health

Andrew Penn, MS, PMHNP is a Professor in the University of California, San Francisco, School of Nursing where his teaching has received the UCSF Academic Senate Distinction in Teaching Award, among other recognitions. Trained as a psychiatric/mental health nurse practitioner, he directs clinical nursing operations for Salma Health an early stage psychiatric interventional treatment clinical company. As a researcher, he has collaborated on psychedelics studies of psilocybin and MDMA in the Translational Psychedelics Research (TrPR) and the Carhart-Harris labs at UCSF. A leading voice in nursing, he is a cofounder of the Organization of Psychedelic and Entheogenic Nurses (OPENurses.org), advocating for the perspective of nurses in psychedelic therapy, he has published on psychedelics in the American Journal of Nursing, Frontiers in Psychiatry, The Journal of Humanistic Psychotherapy, and JAMA. An internationally invited speaker, he has lectured at SXSW, Aspen Health Ideas Festival, TEDx, the Singapore Ministry of Health, and Oxford University and can be found at Andrewpennnp.com.

Steering Committee

Arwen Podesta

MD, DFAPA, DFASAM
Psychiatrist
Podesta Wellness

Boarded in Psychiatry, Addiction Medicine, Forensic Psychiatry and Holistic & Integrative Medicine, Arwen Podesta MD works in Louisiana, with an office in New Orleans. She authored a book on addiction, HOOKED (available on Amazon, see her website, www.podestawellness.com). She was recently awarded the honor of distinguished fellow of the American Psychiatry Association as well as the American Society of Addiction Medicine and is the immediate past President of the Louisiana Psychiatric Medical Association. She consults to the Louisiana governor’s HOPE committee and is a member of the Attorney General’s Opioid Abatement Taskforce. She is a national speaker, she teaches, consults and is an advocate for integrative best practices for those with addiction and psychiatric needs.

MasterClass: Unlocking the Doors of Depression: Neuroplastic and Psychedelic Therapies in MDD

Advances in neuroplasticity research are reshaping the future of depression treatment. This session examines glutamatergic and serotonergic pathways, reviews the latest evidence surrounding investigational psychedelic therapies and psychedelic-assisted psychotherapy, and discusses their potential role within the evolving treatment landscape for MDD.<br><br>Supported by an educational grant from AbbVie Inc.

Speaker

Thursday, September 17 10:15–11:45 AM
Room Great Hall A
Steering Committee

Andrew Penn

MS, PMHNP-BC
Clinical Professor / Director of Clinical Nursing Operations
University of California, San Francisco, School of Nursing / Salma Health

Andrew Penn, MS, PMHNP is a Professor in the University of California, San Francisco, School of Nursing where his teaching has received the UCSF Academic Senate Distinction in Teaching Award, among other recognitions. Trained as a psychiatric/mental health nurse practitioner, he directs clinical nursing operations for Salma Health an early stage psychiatric interventional treatment clinical company. As a researcher, he has collaborated on psychedelics studies of psilocybin and MDMA in the Translational Psychedelics Research (TrPR) and the Carhart-Harris labs at UCSF. A leading voice in nursing, he is a cofounder of the Organization of Psychedelic and Entheogenic Nurses (OPENurses.org), advocating for the perspective of nurses in psychedelic therapy, he has published on psychedelics in the American Journal of Nursing, Frontiers in Psychiatry, The Journal of Humanistic Psychotherapy, and JAMA. An internationally invited speaker, he has lectured at SXSW, Aspen Health Ideas Festival, TEDx, the Singapore Ministry of Health, and Oxford University and can be found at Andrewpennnp.com.

Steering Committee

Charles Raison

MD
Professor
University of Wisconsin-Madison

Charles Raison, MD, is a Professor of Human Ecology and Psychiatry in the Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin-Madison. Dr. Raison also serves as Director of Clinical and Translational Research for Usona Institute, as Director of the Vail Health Behavioral Health Innovation Center, Director of Research on Spiritual Health for Emory Healthcare and as Visiting Professor in the Center for the Study of Human Health at Emory University in Atlanta, GA. Dr. Raison’s research focuses on the examination novel mechanisms involved in the development and treatment of major depression and other stress-related emotional and physical conditions, as well as for his work examining the physical and behavioral effects of compassion training. More recently, Dr. Raison has taken a leadership role in the development of psychedelic medicines as potential treatments for major depression. He was named one of the world’s most influential researchers by Web of Science for the decade of 2010-2019 and has been honored with a Distinguished Alumni Award from Washington University School of Medicine. Dr. Raison received the Raymond Pearl Memorial Award from the Human Biology Association “in recognition of his contributions to our understanding of evolutionary biocultural origins of mental health and illness.” Dr. Raison has also won the 2024 Emory University Science on Spiritual Health Torch and Trumpet Award “for a career devoted to the mental and spiritual health of humanity by responding and attending to suffering with a compassionate heart and a keen scientific mind.”

MasterClass: GAD Care Reimagined: Current Best Practices and the Emerging Role of Psychedelics

Although effective treatments exist for generalized anxiety disorder, many patients continue to experience significant symptoms and functional impairment. This session reviews current standards of care, explores the neurobiology and therapeutic rationale for investigational psychedelic compounds, and evaluates emerging evidence to help clinicians prepare for future treatment advances.<br><br>Supported by an educational grant from Definium Therapeutics.

Speaker

Friday, September 18 10:15–11:45 AM
Room Great Hall A
Steering Committee

Brittany Albright

MD, MPH
Founder and Medical Director of Multidisciplinary and Interventional Psychiatry Practice
Sweetgrass Psychiatry; Medical University of South Carolina

Brittany Albright MD, MPH is a Harvard-trained, triple board-certified psychiatrist with clinical expertise in interventional psychiatry, addiction psychiatry, and obesity medicine. She completed her adult psychiatry residency at the nation’s top ranked program, Massachusetts General Hospital and McLean Hospital and a fellowship in addiction psychiatry at the Medical University of South Carolina, where she serves as an Affiliate Assistant Professor in the Department of Psychiatry & Behavioral Sciences. Dr. Albright is the Founder and CEO of Sweetgrass Psychiatry, South Carolina’s largest physician-owned psychiatry practice with three locations.

Her research and academic work include numerous abstracts presented at national meetings and peer-reviewed manuscripts focused on innovative treatments and psychiatric education. A national speaker and consultant, she serves as President Elect of the South Carolina Psychiatric Association and holds multiple leadership roles with Psych Congress, including co-chair of Psych Congress Elevate and originator of the Private Practice Summit.

She firmly believes in collaborative, comprehensive treatment and the restoration of wellness in her patients and practices psychotherapy with expertise in mentalization based therapy and psychodynamic therapy. She also holds certifications in psychedelic assisted psychotherapy and transcranial magnetic stimulation.

Steering Committee

Andrew Penn

MS, PMHNP-BC
Clinical Professor / Director of Clinical Nursing Operations
University of California, San Francisco, School of Nursing / Salma Health

Andrew Penn, MS, PMHNP is a Professor in the University of California, San Francisco, School of Nursing where his teaching has received the UCSF Academic Senate Distinction in Teaching Award, among other recognitions. Trained as a psychiatric/mental health nurse practitioner, he directs clinical nursing operations for Salma Health an early stage psychiatric interventional treatment clinical company. As a researcher, he has collaborated on psychedelics studies of psilocybin and MDMA in the Translational Psychedelics Research (TrPR) and the Carhart-Harris labs at UCSF. A leading voice in nursing, he is a cofounder of the Organization of Psychedelic and Entheogenic Nurses (OPENurses.org), advocating for the perspective of nurses in psychedelic therapy, he has published on psychedelics in the American Journal of Nursing, Frontiers in Psychiatry, The Journal of Humanistic Psychotherapy, and JAMA. An internationally invited speaker, he has lectured at SXSW, Aspen Health Ideas Festival, TEDx, the Singapore Ministry of Health, and Oxford University and can be found at Andrewpennnp.com.

Psychedelics in Psychiatry: Where the Evidence Stands Today and What Comes Next

Research in psychedelic psychiatry continues to advance rapidly, expanding both scientific understanding and clinical interest. This session will provide a current, evidence-based update on psychedelic-assisted therapies, reviewing recent clinical trial data, evolving regulatory developments, and emerging therapeutic indications. Faculty will examine advances across established and novel compounds, discuss safety and implementation considerations, and address ongoing controversies surrounding access and use. Emphasis will be placed on distinguishing validated clinical evidence from public enthusiasm, helping psychiatrists understand where the field stands today and how psychedelic therapies may realistically integrate into future psychiatric practice.

Speaker

Friday, September 18 3:45–4:45 PM
Room Great Hall A
Steering Committee

Andrew Penn

MS, PMHNP-BC
Clinical Professor / Director of Clinical Nursing Operations
University of California, San Francisco, School of Nursing / Salma Health

Andrew Penn, MS, PMHNP is a Professor in the University of California, San Francisco, School of Nursing where his teaching has received the UCSF Academic Senate Distinction in Teaching Award, among other recognitions. Trained as a psychiatric/mental health nurse practitioner, he directs clinical nursing operations for Salma Health an early stage psychiatric interventional treatment clinical company. As a researcher, he has collaborated on psychedelics studies of psilocybin and MDMA in the Translational Psychedelics Research (TrPR) and the Carhart-Harris labs at UCSF. A leading voice in nursing, he is a cofounder of the Organization of Psychedelic and Entheogenic Nurses (OPENurses.org), advocating for the perspective of nurses in psychedelic therapy, he has published on psychedelics in the American Journal of Nursing, Frontiers in Psychiatry, The Journal of Humanistic Psychotherapy, and JAMA. An internationally invited speaker, he has lectured at SXSW, Aspen Health Ideas Festival, TEDx, the Singapore Ministry of Health, and Oxford University and can be found at Andrewpennnp.com.

Steering Committee

Charles Raison

MD
Professor
University of Wisconsin-Madison

Charles Raison, MD, is a Professor of Human Ecology and Psychiatry in the Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin-Madison. Dr. Raison also serves as Director of Clinical and Translational Research for Usona Institute, as Director of the Vail Health Behavioral Health Innovation Center, Director of Research on Spiritual Health for Emory Healthcare and as Visiting Professor in the Center for the Study of Human Health at Emory University in Atlanta, GA. Dr. Raison’s research focuses on the examination novel mechanisms involved in the development and treatment of major depression and other stress-related emotional and physical conditions, as well as for his work examining the physical and behavioral effects of compassion training. More recently, Dr. Raison has taken a leadership role in the development of psychedelic medicines as potential treatments for major depression. He was named one of the world’s most influential researchers by Web of Science for the decade of 2010-2019 and has been honored with a Distinguished Alumni Award from Washington University School of Medicine. Dr. Raison received the Raymond Pearl Memorial Award from the Human Biology Association “in recognition of his contributions to our understanding of evolutionary biocultural origins of mental health and illness.” Dr. Raison has also won the 2024 Emory University Science on Spiritual Health Torch and Trumpet Award “for a career devoted to the mental and spiritual health of humanity by responding and attending to suffering with a compassionate heart and a keen scientific mind.”

Back to top